Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Interchangeability May Be Losing Luster As Approval Goal

Executive Summary

Pricing now may mean more to payers than whether the product is interchangeable.

You may also be interested in...



EpiPen Familiarity May Prove Tough Hurdle For Generics

With EpiPen injector patent-protected and patients accustomed to its use, finding a substitutable generic device may prove difficult.

FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi

Third biosimilar approved in US brings another iteration of FDA thinking on labeling and naming; etanercept-szzs, which references Amgen's Enbrel, suggests agency might be backtracking on its suffix policy.

FDA To Update Quality Metrics Guidance

It's the only addition to the agency's 2016 agenda.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB001970

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel